These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28848658)

  • 1. Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).
    Ricotta R; Verrioli A; Ghezzi S; Porcu L; Grothey A; Falcone A; Van Cutsem E; Argilés G; Adenis A; Ychou M; Barone C; Bouché O; Peeters M; Humblet Y; Mineur L; Sobrero AF; Hubbard JM; Cremolini C; Prenen H; Tabernero J; Jarraya H; Mazard T; Deguelte-Lardiere S; Papadimitriou K; Van den Eynde M; Pastorino A; Redaelli D; Bencardino K; Funaioli C; Amatu A; Carlo-Stella G; Torri V; Sartore-Bianchi A; Vanzulli A; Siena S
    ESMO Open; 2016; 1(6):e000111. PubMed ID: 28848658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib.
    Arai H; Miyakawa K; Denda T; Mizukami T; Horie Y; Izawa N; Hirakawa M; Ogura T; Tsuda T; Sunakawa Y; Nakajima TE
    Oncotarget; 2017 Dec; 8(66):110530-110539. PubMed ID: 29299166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study.
    Lai E; Puzzoni M; Ziranu P; Cremolini C; Lonardi S; Banzi M; Mariani S; Liscia N; Cinieri S; Dettori M; Mencoboni M; Nappo F; Piacentini G; Labianca R; Zucchelli G; Boccaccino A; Conca V; Pusceddu V; Zaniboni A; Scartozzi M;
    Clin Colorectal Cancer; 2021 Dec; 20(4):e253-e262. PubMed ID: 34429245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
    Sonbol MB; Benkhadra R; Wang Z; Firwana B; Walden DJ; Mody K; Hubbard JM; Murad MH; Ahn DH; Bekaii-Saab T
    Oncologist; 2019 Sep; 24(9):1174-1179. PubMed ID: 31164455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
    Lim Y; Bang JI; Han SW; Paeng JC; Lee KH; Kim JH; Kang GH; Jeong SY; Park KJ; Kim TY
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):757-764. PubMed ID: 27888325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
    Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
    Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
    Amatu A; Schirripa M; Tosi F; Lonardi S; Bencardino K; Bonazzina E; Palmeri L; Patanè DA; Pizzutilo EG; Mussolin B; Bergamo F; Alberti G; Intini R; Procaccio L; Arese M; Marsoni S; Nichelatti M; Zagonel V; Siena S; Bardelli A; Loupakis F; Di Nicolantonio F; Sartore-Bianchi A; Barault L
    Front Oncol; 2019; 9():622. PubMed ID: 31355139
    [No Abstract]   [Full Text] [Related]  

  • 10. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
    J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib.
    Vanwynsberghe H; Verbeke X; Coolen J; Van Cutsem E
    Clin Colorectal Cancer; 2017 Dec; 16(4):377-380. PubMed ID: 28454726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial.
    Pasqualetti G; Schirripa M; Dochy E; Fassan M; Ziranu P; Puzzoni M; Scartozzi M; Alberti G; Lonardi S; Zagonel V; Monzani F; Loupakis F
    Eur J Cancer; 2020 Jul; 133():66-73. PubMed ID: 32446145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study.
    Lucidarme O; Wagner M; Gillard P; Kim S; Bachet JB; Rousseau B; Mazard T; Louvet C; Chibaudel B; Cohen R; Garcia-Larnicol ML; Gobert A; Henriques J; André T
    Cancer Imaging; 2019 Dec; 19(1):85. PubMed ID: 31818317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603).
    Oki E; Kawahira M; Kusumoto T; Yuki S; Hatanaka K; Kobayashi Y; Nishie A; Kawanami S; Makiyama A; Saeki H; Sakamoto S; Komatsu Y; Shimokawa M; Mori M; Esaki T
    Oncology; 2020; 98(10):719-726. PubMed ID: 32640458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
    Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
    Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
    Komori A; Taniguchi H; Hamauchi S; Masuishi T; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
    Oncology; 2017; 93(5):329-335. PubMed ID: 28866662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.
    Pavlakis N; Shitara K; Sjoquist K; Martin A; Jaworski A; Tebbutt N; Bang YJ; Alcindor T; O'Callaghan C; Strickland A; Rha SY; Lee KW; Kim JS; Bai LY; Hara H; Oh DY; Yip S; Zalcberg J; Price T; Simes J; Goldstein D
    J Clin Oncol; 2024 Oct; ():JCO2400055. PubMed ID: 39365958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.